Dopamine and schizophrenia - PubMed (original) (raw)
Comparative Study
Dopamine and schizophrenia
T J Crow et al. Lancet. 1976.
Abstract
The antipsychotic actions and extra-pyramidal side-effects of neuroleptic drugs are strongly correlated with their ability to block central dopaminergic transmission. It is argued that the former are more closely related to actions on dopaminergic mechanisms in the "mesolimbic dopamine" system, and the latter to similar actions in the striatum. Although the amphetamine psychosis closely resembles paranoid schizophrenia and may be due to excess dopamine release, clinical, biochemical, and endocrine studies suggest that dopaminergic overactivity is not a necessary concomitant of schizophrenic illnesses. It is suggested that the primary defect in schizophrenia does not lie in the dopamine neuron. It remains to be excluded that the receptors, particularly in the mesolimbic dopamine areas, become supersensitive, or that there is a deficit in a system which normally acts in antiagonism to the to the mesolimbic dopamine system.
Similar articles
- The nucleus accumbens--possible site of antipsychotic action of neuroleptic drugs?
Crow TJ, Deakin JF, Longden A. Crow TJ, et al. Psychol Med. 1977 May;7(2):213-21. doi: 10.1017/s0033291700029287. Psychol Med. 1977. PMID: 560024 - Dopamine antagonism by thioridazine in schizophrenia.
Meltzer HY, Sachar EJ, Frantz AG. Meltzer HY, et al. Biol Psychiatry. 1975 Feb;10(1):53-7. Biol Psychiatry. 1975. PMID: 1120175 - Brain dopamine and behaviour. A critical analysis of the relationship between dopamine antagonism and therapeutic efficacy of neuroleptic drugs.
Crow TJ, Gillbe C. Crow TJ, et al. J Psychiatr Res. 1974;11:163-72. doi: 10.1016/0022-3956(74)90088-0. J Psychiatr Res. 1974. PMID: 4461788 No abstract available. - Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
Hornykiewicz O. Hornykiewicz O. Annu Rev Pharmacol Toxicol. 1977;17:545-59. doi: 10.1146/annurev.pa.17.040177.002553. Annu Rev Pharmacol Toxicol. 1977. PMID: 17361 Review. No abstract available. - [Schizophrenia and dopamine (author's transl)].
Toru M. Toru M. Tanpakushitsu Kakusan Koso. 1978;23(4):303-16. Tanpakushitsu Kakusan Koso. 1978. PMID: 26107 Review. Japanese. No abstract available.
Cited by
- Dopaminergic mechanisms in schizophrenia.
Iversen LL. Iversen LL. Proc R Soc Med. 1977;70(Suppl 10):1-4. Proc R Soc Med. 1977. PMID: 20919311 Free PMC article. No abstract available. - Neuropharmacological profile of an atypical antipsychotic, NRA0562.
Hirota S, Kawashima N, Chaki S, Okuyama S. Hirota S, et al. CNS Drug Rev. 2003 Winter;9(4):375-88. doi: 10.1111/j.1527-3458.2003.tb00261.x. CNS Drug Rev. 2003. PMID: 14647530 Free PMC article. Review. - Mechanisms of action of atypical antipsychotic drugs: a critical analysis.
Kinon BJ, Lieberman JA. Kinon BJ, et al. Psychopharmacology (Berl). 1996 Mar;124(1-2):2-34. doi: 10.1007/BF02245602. Psychopharmacology (Berl). 1996. PMID: 8935797 Review. - Genetics and schizophrenic behavior.
Kahn E. Kahn E. Psychiatr Q. 1980 Winter;52(4):251-69. doi: 10.1007/BF01080286. Psychiatr Q. 1980. PMID: 7017784 Review. No abstract available. - Haloperidol plasma levels and clinical response in paranoid schizophrenics.
Linkowski P, Hubain P, von Frenckell R, Mendlewicz J. Linkowski P, et al. Eur Arch Psychiatry Neurol Sci. 1984;234(4):231-6. doi: 10.1007/BF00381354. Eur Arch Psychiatry Neurol Sci. 1984. PMID: 6526061